Ikena Oncology Files Q1 2025 10-Q, Details Merger & Loan
Ticker: IMA · Form: 10-Q · Filed: May 8, 2025 · CIK: 1835579
| Field | Detail |
|---|---|
| Company | Ikena Oncology, INC. (IMA) |
| Form Type | 10-Q |
| Filed Date | May 8, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, merger, loan, financials
Related Tickers: IMAG
TL;DR
IKNA Q1 10-Q out: Merger w/ Inmagene, loan details, and fair value updates. Check financials.
AI Summary
Ikena Oncology, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported on its financial condition and business operations, including details related to its merger agreement with Inmagene and a loan agreement. Specific financial data points such as fair value measurements and employee severance compensation were also detailed.
Why It Matters
This filing provides investors with an update on Ikena Oncology's financial health and strategic activities, including significant corporate actions like mergers and loan agreements.
Risk Assessment
Risk Level: medium — The filing details financial performance and strategic agreements, which can significantly impact the company's future, warranting a medium risk assessment.
Key Numbers
- 2025-03-31 — Reporting Period End Date (The end date for the financial reporting period covered by the 10-Q.)
- 2025-05-08 — Filing Date (The date the 10-Q was officially filed with the SEC.)
- 2024-12-23 — Loan Agreement Date (Specific date related to a loan agreement mentioned in the filing.)
Key Players & Entities
- Ikena Oncology, Inc. (company) — Filer of the 10-Q
- Inmagene (company) — Party to the Merger Agreement
- Pionyr Immunotherapeutics Inc (company) — Mentioned in relation to a member
- 0000950170-25-066411 (other) — Accession Number for the filing
- 20250331 (date) — Conformed Period of Report
FAQ
What was the net loss for Ikena Oncology in the quarter ending March 31, 2025?
The filing does not explicitly state the net loss for the quarter ending March 31, 2025, in the provided snippet. Further review of the full 10-Q document is required for this specific financial figure.
What is the status of the merger agreement with Inmagene as of March 31, 2025?
The filing mentions the 'MergerAgreementMember' and 'InmageneMember', indicating the merger agreement is a relevant topic for the period ending March 31, 2025, but does not detail its current status or completion.
What types of financial instruments were valued at fair value on March 31, 2025?
The filing indicates that 'us-gaap:FairValueMeasurementsRecurringMember' and 'us-gaap:FairValueInputsLevel2Member' were applicable as of March 31, 2025, suggesting recurring fair value measurements were performed, likely on financial assets or liabilities.
Were there any significant employee severance costs incurred during the first quarter of 2025?
Yes, the filing references 'ikna:EmployeeSeveranceNonCashCompensationMember' and 'ikna:EmployeeSeveranceAndRetentionCashCompensationMember' for the period of January 1, 2025, to March 31, 2025, indicating these costs were accounted for.
What is the company's primary business as indicated by its SIC code?
The Standard Industrial Classification (SIC) code provided is [2836], which corresponds to 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)', indicating the company's focus is on biological product development.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 8, 2025 regarding Ikena Oncology, Inc. (IMA).